Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Biogen Japan COO Ajai Sulekh Named as New President
November 1, 2018
- Daiichi Sankyo to Discontinue Development of Intradermal Flu Vaccine
November 1, 2018
- Astellas Sales Up 1.1% Driven by Xtandi, OAB Drugs, despite Slump in Japan Business
November 1, 2018
- Sanofi, Daiichi Sankyo to Terminate Marketing Partnership for Hib Vaccine in Japan; Sanofi to Take Over Sales from Jan.
November 1, 2018
- Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions
October 31, 2018
- Mitsubishi Tanabe Sales Slip 1.7% as Radicava Boon Fails to Counter Japan Drop
October 31, 2018
- Mitsubishi Tanabe Paints Murky Outlook for US Sales Target on Parkinson’s Development Delay
October 31, 2018
- Nesp Biosame to Hit Japan Market in July-September 2019
October 31, 2018
- Otsuka Pharmaceutical Factory to Jointly Develop Regenerative Medicine Products with Startup
October 31, 2018
- Shionogi’s Half-Year Profits Renew Records, but Crestor Generics Weigh on Topline
October 30, 2018
- Shionogi Chief Confident about 70% Market Share for Xofluza in Japan
October 30, 2018
- Europe OKs Xtandi for All CRPC Cases
October 30, 2018
- JCR Initiates Development of Temcell for Epidermolysis Bullosa
October 30, 2018
- Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
October 29, 2018
- Fujifilm Signs MOU on Clinical Development of Favipiravir in China with 3 Chinese Partners
October 29, 2018
- Taiho’s Lonsurf Grabs US Priority Review Status for Gastric Cancer
October 29, 2018
- Daiichi Sankyo, Merck KGaA, Pfizer to Collaborate for PI of DS-8201, Bavencio, and DDR Combo
October 29, 2018
- Lemborexant Improves Nighttime Activity in AD Patients with Irregular Sleep-Wake Rhythm Disorder in PII: Eisai
October 29, 2018
- Eisai, Biogen Tout BAN2401’s Clinical Effect Regardless of APOE4 Mutation
October 29, 2018
- Shionogi, Osaka Univ. to Collaborate on Medical Data Science for Effective Use of Real-World Data
October 26, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…